GRFT-M04 - Medical / Health Care
GRFT-M04 project is a combination device associating a bone resorption inhibitor (bisphosphonate), a highly injectable calcium phosphate cement and a radio opacifier for the spinal applications.
This R&D project is aiming at therapeutic and prophylactic applications for osteoporotic patients:
- short-term expected benefit is an enhanced strength and resistance in fragile bone at high risk of fracture.
- long term expected benefit is the optimization of the reconstruction of healthy bone at the site of implantation throughout the resorption process of the device followed by its replacement bynatural bone, through inhibition of the excessive and unbalanced osteoclastic activity.
The targeted indications include bone anchorage augmentation and secondary fracture prevention in the proximal femur or in the spine in osteoporotic patients.
This proprietary and patented technology is a unique combination device to propose local therapeutic or prophylactic solutions for osteoporotic patients.
Preclinical data show significant reinforcement and effective secondary action on trabecular bone structure. Regulatory route has been confirmed, and a first market introduction is expected in 2020-2021.